Kidney disease is on the rise. An aging population, improved medical diagnosis capabilities and poor lifestyle choices are leading to a rise in incidence of certain diseases. These combined factors contribute to the fact that 1 in 3 American adults are currently at risk for developing kidney disease.
In fact, 26 million Americans suffer from some type of kidney disease, and most are unaware of the problem. Kidney disease kills over 90,000 Americans every year — more than breast and prostate cancer combined.
The good news is that we are making strides in this area. Today doctors are able to recognize diseases that impact the kidney more often and earlier, and that can save lives. Additionally, as the incidence of these diseases grows so too does medicine’s focus on finding treatments for both well-known and rare conditions that affect this vital organ.
One of the lesser-known diseases that can injure the kidneys, potentially leading to transplant, is called vasculitis. About 100,000 Americans each year are hospitalized for the care of vasculitis. This disease can affect blood vessels throughout the body, and as the kidney is effectively composed of blood vessels, it can be severely damaged by this disorder. If vasculitis isn’t aggressively treated early on, it often progresses to end-stage kidney disease, requiring dialysis or a kidney transplant. Fortunately, a recently published study shows that there are treatments safe for remission-induction in patients with severe vasculitis.
During a recent phone interview, Dr. Jeff Giullian, with South Denver Nephrology Associates shared with me the key facts about kidney disease, vasculitis and current treatment options, and research happening to help with kidney disease prevention. Take a listen to the interview below.
Jeffrey A. Giullian, MD, MBA
Dr. Jeffrey A. Giullian is a nephrologist and partner at South Denver Nephrology Associates, in Denver, Colorado, where he practices both general and transplant nephrology, including care of patients with chronic kidney disease (CKD), end stage renal disease (ESRD), immunosupression, hypertension and kidney stones. In addition to his clinical responsibilities, Dr. Giullian has an active research clinic focusing on phase 2 and 3 clinical trials. He is active in renal research for patients with electrolyte abnormalities, polycystic kidney disease and diabetes.
Currently, Dr. Giullian is the Chairman of Medicine at Castle Rock Adventist Hospital, the Chief of Nephrology at Swedish Hospital, and a member of the Porter Hospital Kidney and Pancreas Transplant team. He is also a Group Medical Director for the APEX group of DaVita Dialysis covering dialysis centers in nine states.
After earning a MD from Vanderbilt School of Medicine in 2001, Dr. Giullian completed an internal medicine residency at Baylor College of Medicine in Houston, TX. He served as Baylor’s Chief Medical Resident from 2004-2005. After completing his residency, he returned to Vanderbilt University Medical center for his nephrology training. During this time, from 2006-2007, he was Vanderbilt University Medical Center’s Chief Fellow for the division of nephrology.
In addition to his MD degree, Dr. Giullian holds a MBA degree from the University of Colorado at Denver.